Tumorigenic de-differentiation: the alternative splicing way

Abstract

The mechanism of acquisition of tumorigenic properties by somatic cells at the onset of cancer and later during relapse is a question of paramount importance in cancer biology. We have recently discovered a Muscleblind like-1 (MBNL1)-driven alternative-splicing mediated mechanism of tumorigenic de-differentiation that is associated with poor prognosis, relapse and metastasis in common cancer types.

Keywords

• mbnl1
• map2k7
• jnk
• jnk inhibitors
• alternative splicing
• cancer cell de-differentiation
• cancer stem cells
• rna binding proteins
• splice factors